Clinical Trial – Effect of Secukinumab in PsA – Psoriasis Arthritis

  • 1

1 Answer

These messages are for mutual support and information sharing only. Always consult your doctor before trying anything you read here.
The study is designed to investigate, in detail, the clinical and molecular effects of secukinumab(Cosentyx) in the treatment of Psoriasis Arthritis. The investigators will also make use of the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab.
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Exploration of the Dynamic Interaction Between IL-17, IL-17 Inhibition With (Secukinumab) and Neutrophils in Psoriatic Arthritis in Vitro and ex Vivo With Exploratory Study on the Potential Role of Vitamin D
Study Start Date : October 2016
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : August 2018
Contact: Laurence S Loubiere, PhD Identifier: NCT02854163
For enrollment please visit